pci-32765 has been researched along with Mycoses* in 7 studies
2 review(s) available for pci-32765 and Mycoses
Article | Year |
---|---|
Fungal Infections Potentiated by Biologics.
Biologic therapies including monoclonal antibodies, tyrosine kinase inhibitors, and other agents represent a notable expansion in the pharmacotherapy armamentarium in treatment of a variety of diseases. Many of these therapies possess direct or indirect immunosuppressive and immunomodulatory effects, which have been associated with bacterial, viral, and fungal opportunistic infections. Careful screening of baseline risk factors before initiation, targeted preventive measures, and vigilant monitoring while on active biologic therapy mitigate these risks as use of biologics becomes more commonplace. This review compiles reported evidence of fungal infections associated with these agents with a focus on the tumor necrosis factor-α inhibitor class. Topics: Adenine; Antigens, CD; Biological Products; Clinical Trials as Topic; Humans; Mycoses; Piperidines; Tumor Necrosis Factor-alpha | 2020 |
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non-Aspergillus invasive mould infections (NAIMIs) in this setting, OBJECTIVES: To review our recent experience and the published literature on the topic.. We present a case of invasive sinusitis caused by Fusarium in a patient with refractory chronic lymphocytic leukaemia (CLL) who was treated with IBR and review the 12 published cases of NAIMIs during IBR.. Nearly all cases of NAIMIs in the setting of IBR use were encountered in patients with CLL. Mixed fungal infections, brain involvement and late-onset infections were common.. Although rare, NAIMIs should be considered in patients who receive IBR. Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi; Fusariosis; Fusarium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucorales; Mycoses; Piperidines | 2020 |
5 other study(ies) available for pci-32765 and Mycoses
Article | Year |
---|---|
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycoses; Piperidines; Pyrazoles; Steroids | 2021 |
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.
Topics: Adenine; B-Lymphocytes; Consensus; Humans; Immunosuppressive Agents; Mycoses; Neoplasms; Piperidines | 2020 |
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles | 2020 |
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Patients; Piperidines; Pyrazoles; Pyrimidines | 2020 |
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence | 2019 |